News Releases

Date Title and Summary
Toggle Summary electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue
Extension maintains listing through March 17, 2026 ROCKAWAY, N.J. , Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue to be listed in the United Kingdom’s National
Toggle Summary electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
ROCKAWAY, N.J. , Oct. 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a treatment protocol for nVNS. U.S. Patent No.
Toggle Summary Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress
“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH) “NOVIS” Clinical Trial (n=150) of nVNS for the acute treatment of Ischemic Stroke will complete recruitment in 2023 ROCKAWAY, N.J. , Oct.
Toggle Summary electroCore to Announce Third Quarter Financial Results on Wednesday, November 8
ROCKAWAY, N.J. , Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2023, after the close of the market on Wednesday,
Toggle Summary electroCore to Participate in the Lytham Partners Fall 2023 Virtual Investor Conference
ROCKAWAY, N.J. , Oct. 05, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger , will be participating in the Lytham Partners Fall 2023 Investor Conference taking place virtually
Toggle Summary gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)
Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD ROCKAWAY, N.J. , Sept. 27, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of two
Toggle Summary electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
ROCKAWAY, N.J. , Sept. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to non-invasive nerve stimulation with mobile devices. U.S.
Toggle Summary electroCore to Participate in the LD Micro Main Event XVI Conference
ROCKAWAY, N.J. , Sept. 25, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger , will present at the LD Micro Main Event XVI Conference in Los Angeles, California from October 3 –
Toggle Summary electroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference
ROCKAWAY, N.J. , Sept. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger , will present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference . Mr.
Toggle Summary electroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
ROCKAWAY, N.J. , Sept. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger , will present at the H.C. Wainwright 25th Annual Global Investment Conference . H.C.